News | March 19, 2026
Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
SPARK has extended its influence to an additional 9.47 million students worldwide
SPARK has extended its influence to an additional 9.47 million students worldwide
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Subscribe To Our Newsletter & Stay Updated
